Core Viewpoint - Guangzhou Deep Medical Instrument Technology Co., Ltd. has completed its Series A financing, indicating strong interest from medical investment funds in the field of microscope surgical robots and recognition of the company's unique technology and execution capabilities [1][3]. Group 1: Company Overview - Deep Medical is a founding member of the Microsurgery Branch of the China Medical Device Industry Association, focusing on intelligent devices for all aspects of microscope surgery [3][17]. - The flagship product, FUNZAR microscope surgical robot, has been recognized as a significant advancement in microsurgery for two consecutive years (2024/2025) and was ranked first among the top five advancements in 2025 [3][17]. Group 2: Technological Innovation - FUNZAR is the world's first modular universal microscope surgical robot system, aiming to redefine the standards of microscope surgery with its innovative design [8][9]. - The system features hand-eye integration with a magnification capability of 10-100 times, allowing surgeons to operate with precision [8]. - FUNZAR employs a modular design with multiple robotic arms, enabling autonomous operations without the need for assistant surgeons [9][10]. Group 3: Clinical Progress - Since its official operation in April 2024, Deep Medical has rapidly progressed through product development, animal testing, and clinical trials, achieving the first clinical enrollment in December 2024 [12]. - Clinical trials for FUNZAR are currently underway in top hospitals across Beijing, Shanghai, Changsha, and Guangzhou, demonstrating its technical advantages and stability [12]. Group 4: Investment and Support - The company has received continuous support from investors like Wanfu Chuanggu and Kangjun Capital, who recognize the strategic value of universal microscope surgical robots [13][14]. - Kangjun Capital emphasizes the innovative technology and execution capabilities of the team, highlighting the potential for FUNZAR to address clinical challenges in microsurgery [14][16].

Group 1 - The core viewpoint of the news is that Guangzhou Deep Medical Instrument Technology Co., Ltd. has completed a multi-million yuan Pre-A round financing, which will accelerate its clinical, registration, and market expansion efforts with the support of Wanfu Chuanggu [1][2] - The flagship product, FUNZAR, is an advanced surgical robot designed for microsurgery, featuring dual-arm 16 degrees of freedom, a 60x 4K ultra-high-definition 3D digital visual navigation system, and sub-micron level spatial positioning technology [1][2] - FUNZAR has successfully completed several clinical trials, including the world's first Alzheimer's deep cervical lymphatic end-to-end anastomosis surgery, demonstrating its feasibility and effectiveness in various microsurgical procedures [1][2] Group 2 - The chairman and founder of Deep Medical, Dr. Xia Jun, emphasized the strong demand for robotic assistance in microsurgery due to its complexity and the physical strain on surgeons [2] - Wanfu Chuanggu's investment leader, Mr. She Jin, highlighted significant breakthroughs in high-precision motion control and the adaptability of FUNZAR to microsurgical scenarios, which have been validated through preliminary clinical trials [2][3] - Strong Cloud Capital's Northern Region leader, Ms. Yan Guopei, noted the impressive product detail control, team efficiency, and comprehensive patent layout of Deep Medical, positioning it as a leader in the promising field of surgical robotics [3]